Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 12, Issue 9, Pages 1277-1289Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2012.707178
Keywords
arthritis; biological therapy; interleukin-6; randomised controlled trial; rheumatoid arthritis; tocilizumab
Funding
- Abbott
- Chugai
- Pfizer
- MSD
- Merck
- Sharp
- Dohme
- Cancer Research UK
- Versus Arthritis [18475] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10299] Funding Source: researchfish
Ask authors/readers for more resources
Introduction: The introduction of biological treatments has improved the outlook for patients diagnosed with rheumatoid arthritis. There are now a range of different agents, targeting various pathways involved in the inflammatory process. Tocilizumab, a fully humanised anti-interleukin-6 receptor monoclonal antibody is licensed for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. Areas covered: This article reviews and appraises the available evidence regarding the efficacy and safety of tocilizumab in rheumatoid arthritis, as identified in PubMed and Embase searches. Expert opinion: Clinical trial data suggest that tocilizumab has similar efficacy both clinically and in reducing structural progression to that seen with the TNF inhibitors. Patients who might be particularly suitable for tocilizumab are those who have failed multiple TNF inhibitors, those with a high inflammatory response as part of their disease and those unable to tolerate methotrexate, given the good responses seen with monotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available